Arca
Skip to content
Tools
Tools

EDNRA, EDNRB: Endothelin receptor, ET-A/ET-B

Family in Homo sapiens that 5 drugs act on.

  • Drugs that act on it: 5
  • Approved: 5
  • In phases 1 to 3: 0
  • Sponsors: 4

Who is on it, and how far along

Every drug ChEMBL records acting on EDNRA, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 5

Approved5

  • Bosentan
  • Ambrisentan
  • Macitentan
  • Aprocitentan
  • Sitaxentan

Phase 30

    Phase 20

      Phase 10

        Sponsors

        Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Endothelin receptor, ET-A/ET-B antagonist.
        BosentanBoxed warningApprovedJohnson & JohnsonSmall moleculeAntagonist13
        AmbrisentanBoxed warningApprovedGilead SciencesSmall moleculeAntagonist9
        MacitentanBoxed warningApprovedJohnson & JohnsonSmall moleculeAntagonist9
        AprocitentanBoxed warningApprovedIdorsiaSmall moleculeAntagonist1
        SitaxentanWithdrawnApprovedPfizerSmall moleculeAntagonist1

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 22 in all, from ClinicalTrials.gov.
        A Study of Opsynvi in Adults Participants With Pulmonary Arterial Hypertension in KoreaMacitentan—Not yet recruitingJanssen Korea, Ltd., KoreaOct 22, 2026
        Endothelin Role In COronary MicrocirculationBosentanNot applicableActive, not recruitingLiverpool University Hospitals NHS Foundation TrustJun 26, 2026
        A Study Evaluating Aprocitentan Tablets(SYH9108) for the Treatment of Resistant HypertensionAprocitentanPhase 3Not yet recruitingCSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.Jun 9, 2026
        Efficacy and Mechanisms of Macitentan for Non-Coronary Obstructive AnginaMacitentanEarly phase 1RecruitingChina-Japan Friendship HospitalFeb 6, 2026
        COMMODITIES Trial: Initial Dual Oral Therapy vs Monotherapy in PAH With Cardiovascular ComorbiditiesAmbrisentanPhase 3RecruitingAssistance Publique - Hôpitaux de ParisNov 24, 2025
        Clinical Trial to Evaluate the Efficacy and Safety in Concomitant Administration of Macitentan and Dapagliflozin in Patients With Heart Failure With Mildly Reduced and Preserved Ejection Fraction (HFmrEF and HFpEF) and Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH)MacitentanPhase 4RecruitingGachon University Gil Medical CenterAug 28, 2025
        Nefecon and Ambrisentan in IgA NephropathyAmbrisentanPhase 4RecruitingThe First Hospital of Jilin UniversityJun 22, 2025
        The Impact of ERA Switching on Risk Stratification in Pulmonary Arterial HypertensionAmbrisentan, Bosentan—RecruitingUniversity of Sao Paulo General HospitalJun 10, 2025
        Ambrisentan for Early Low-Risk Pulmonary Arterial HypertensionAmbrisentanNot applicableNot yet recruitingNanjing First Hospital, Nanjing Medical UniversityMay 23, 2025
        Comparison of Sequential to Initial Combination Therapy in PAHAmbrisentanNot applicableRecruitingSecond Affiliated Hospital, Zhejiang University, School of MedicineMay 13, 2025
        Bosentan in the Treatment of Giant Cell ArteritisBosentanPhase 2Not yet recruitingAssistance Publique - Hôpitaux de ParisMay 4, 2025
        Dapagliflozin and Endothelin Receptor Antagonism in Large Vessel Vasculitis (DERAIL-LVV)BosentanPhase 2RecruitingUniversity of EdinburghMar 20, 2025
        Evaluation of the Efficacy of MACitentan in the Treatment of CoronaryMICrovascular Angina (MACMIC)MacitentanEarly phase 1RecruitingChina-Japan Friendship HospitalFeb 6, 2025
        Efficacy and Safety of Triple-targeted Drug Therapy in Treatment-naive Patients With Non-low-risk PAH: A Real-world, Multicenter StudyMacitentan—RecruitingQianfoshan HospitalDec 31, 2024
        Efficacy of Endothelin Receptor Antagonism in Coronary Artery SpasmBosentanPhase 2 / Phase 3Enrolling by invitationRadboud University Medical CenterMay 29, 2024
        Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I PatientsAmbrisentan, Bosentan, MacitentanPhase 4RecruitingAOP Orphan Pharmaceuticals AGMar 19, 2024
        Endothelin Receptor Antagonism With Ambrisentan to Treat Hepatorenal SyndromeAmbrisentanPhase 2Active, not recruitingNoorik Biopharmaceuticals AGFeb 13, 2024
        A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other OptionMacitentanPhase 3RecruitingActelionJan 5, 2022
        Endothelin-1 Receptor Blockade in Resistant HypertensionBosentanPhase 2RecruitingUniversity Hospital, RouenMay 14, 2020
        Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)Bosentan—RecruitingDuke UniversityFeb 20, 2020
        Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial HypertensionAmbrisentan, MacitentanPhase 3Active, not recruitingActelionFeb 18, 2020
        COMPERA / COMPERA-KIDSSitaxentan—RecruitingTechnische Universität DresdenMay 4, 2011

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2096678, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.